# Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer
Canonical URL: https://biopharmsignal.com/news/CMPX/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-2-3--633662ff
Ticker: CMPX
Company: Compass Therapeutics
Source: Compass Therapeutics
Published: 2026-04-24 20:00 EST
## Summary

Webcast scheduled for Monday, April 27, 2026 at 8:00am ET. BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a...

## Article Body
Webcast scheduled for Monday, April 27, 2026 at 8:00am ET.

BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on Monday, April 27, 2026 at 8:00am ET to review topline secondary endpoints from its Phase 2/3 COMPANION-002 clinical study assessing tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer (BTC).

Conference Call and Webcast Presentation:

Date and Time: Monday, April 27, 2026 at 8:00am ET

Toll Free: 1-877-407-9716

International: 1-201-493-6779

Conference ID: 13760371

Webcast Presentation: https://viavid.webcasts.com/starthere.jsp?ei=1761459&tp_key=efc315f5a6

A replay of the webcast and accompanying presentation will be available, for 90 days, following the event on the “ Events ” page under the Investors section of the Company’s website.

About Compass Therapeutics Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, MA. Compass is a clinical-stage, oncology-focused biopharmaceutical company discovering and developing proprietary antibody-based therapeutics to treat multiple diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system and tumor growth. Compass has a robust pipeline of novel product candidates designed to target multiple key biological pathways to drive an effective anti-tumor response, including angiogenesis modulation, immune activation within the tumor microenvironment, and reduction of tumor-driven immunosuppression. The company is advancing discovery candidates through clinical development to commercial-stage assets. For more information, visit www.compasstherapeutics.com .

Investor Contact ir@compasstherapeutics.com

Media Contact Anna Gifford, Chief of Staff media@compasstherapeutics.com 617-500-8099
## Recent Company News
- 2026-07-17 14:42 EST — [Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026](https://biopharmsignal.com/news/CMPX/compass-therapeutics-announces-tovecimig-data-accepted-for-an-oral-presentation--350ddb60) — Source: Compass Therapeutics
- 2026-05-28 11:30 EST — [Compass Therapeutics to Participate in Upcoming June Investor Events](https://biopharmsignal.com/news/CMPX/compass-therapeutics-to-participate-in-upcoming-june-investor-events-1eb21840) — Source: Compass Therapeutics
- 2026-05-21 21:00 EST — [Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting](https://biopharmsignal.com/news/CMPX/compass-therapeutics-to-present-promising-phase-1-clinical-data-for-ctx-8371-in--211bb911) — Source: Compass Therapeutics
- 2026-05-12 11:30 EST — [Compass Therapeutics to Participate in Upcoming May Investor Events](https://biopharmsignal.com/news/CMPX/compass-therapeutics-to-participate-in-upcoming-may-investor-events-a79d8121) — Source: Compass Therapeutics
- 2026-05-05 11:30 EST — [Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/CMPX/compass-therapeutics-reports-2026-first-quarter-financial-results-and-provides-c-7bfdf19a) — Source: Compass Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)